Optimisation of a selection strategy for drug resistance osteosarcoma cell lines

Low, Kaan, Hills, Frank ORCID logoORCID: https://orcid.org/0000-0001-8235-7545, Roberts, Helen C. ORCID logoORCID: https://orcid.org/0000-0003-1974-0319 and Stordal, Britta K. ORCID logoORCID: https://orcid.org/0000-0002-7892-951X (2019) Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. In: 2019 NCRI Cancer Conference, 03-05 Nov 2019, Glasgow, UK. . [Conference or Workshop Item]

Abstract

Background: Osteosarcoma is the most common primary malignant bone tumour and also the second highest cause of cancer-related death in children and teenagers. Forty percent of patients will experience systemic relapse after chemotherapy, and this is likely to associated with chemotherapy drug resistance. We used a clinically-relevant comparative-selection strategy to develop novel chemo-resistant cell lines. We aim to investigate the mechanisms of resistance that arise from different exposures of cisplatin, doxorubicin and methotrexate.

Method: An acid phosphatase assay was performed to determine drug resistance. Doses of the drugs that used in the pulse selection strategy was optimised from inhibitory concentration (IC) values of cytotoxicity assay ranging from IC60to IC80.

Results: HOS-143B displays a higher level of resistance to cisplatin and methotrexate compared to MG-63 with IC50values 1.05 ±0.04mg/ml and 0.25 ±0.04mg/ml for cisplatin, and 28.23 ±2.05ng/ml and 16.85 ±0.64ng/ml for methotrexate respectively. However, HOS-143B displays a lower level of resistance to doxorubicin with IC IC50values 12.00 ±0.18nM and 25.64 ±0.68nM respectively. Interestingly, resistance to methotrexate developed quicker and at a higher level in MH-63 (marginally metastatic) compared to HOS-143B (highly metastatic). MG-63/MTXR3 displays the highest level of resistance to methotrexate with 25-fold, p=0.0069 while HOS-143B/MTXR3 shows a lower level of resistance with 2.3-fold, p=0.004. MG-63/CISR3, HOS-143B/CISR3 and HOS-143B/DOXR3 all has resistance to their respective agents (1.6-2.9 fold, p=0.0006-0.034). Interestingly, there was no significant drug resistance established in the cell lines treated with the triplet combination of cisplatin, doxorubicin and methotrexate. This suggests that cell models developed with a single drug may not reflect chemo-resistant in the clinical treatment of osteosarcoma.

Conclusion: In conclusion, the developed resistance models are valuable tools with which to study the resistance of anticancer drugs and to identify the methods to overcome resistance in osteosarcoma.

Item Type: Conference or Workshop Item (Poster)
Sustainable Development Goals:
Research Areas: A. > School of Science and Technology > Natural Sciences > Biomarkers for Cancer group
Item ID: 35369
Useful Links:
Depositing User: Dr Britta Stordal
Date Deposited: 07 Jul 2022 16:40
Last Modified: 07 Jul 2022 16:40
URI: https://eprints.mdx.ac.uk/id/eprint/35369

Actions (login required)

View Item View Item

Statistics

Activity Overview
6 month trend
0Downloads
6 month trend
13Hits

Additional statistics are available via IRStats2.